82 results
DEFM14A
CERE
Cerevel Therapeutics Holdings Inc
18 Jan 24
Proxy related to merger
7:44am
candidates to be less effective than expected or have an unacceptable safety or tolerability profile; uncertainties inherent in the product development … the necessary regulatory approvals or a delay in receiving such
approvals, which, among other things, may be caused by unexpected safety or manufacturing
PRER14A
CERE
Cerevel Therapeutics Holdings Inc
18 Jan 24
Preliminary revised proxy
7:19am
results may show the product candidates to be less effective than expected or have an unacceptable safety or tolerability profile; uncertainties inherent … by unexpected safety or manufacturing issues. In addition, the Board considered the fact that Cerevel has no prior marketing, sales and distribution experience
PREM14A
CERE
Cerevel Therapeutics Holdings Inc
5 Jan 24
Preliminary proxy related to merger
5:13pm
: clinical trial results may show the product candidates to be less effective than expected or have an unacceptable safety or tolerability profile … be caused by unexpected safety or manufacturing issues. In addition, the Board considered the fact that Cerevel has no prior marketing, sales
DEFA14A
oldqc4a53z7f7gy zac
7 Dec 23
Additional proxy soliciting materials
8:02am
8-K
EX-2.1
n062x 4oey
7 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
8:00am
8-K
EX-99.1
qnp7f147m1c135qbjhe
7 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
8:00am
8-K
EX-99.1
refz0sdiujygo5lbd0
1 Nov 23
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
6:39am
8-K
EX-1.1
yk3nuwrv1uwb
12 Oct 23
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
4:19pm
424B5
5ck67jfjp gheny
12 Oct 23
Prospectus supplement for primary offering
4:16pm
424B5
2d0j9arj
11 Oct 23
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.1
n0ecljujxp3aqqy bm9
2 Aug 23
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
6:43am
8-K
EX-99.1
5wo4jbgr5xmakhown
3 May 23
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
6:39am
8-K
EX-99.1
nxlqc8sb
19 Dec 22
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
8:00am